Stelara (J&J Janssen Cilag) reduces damage in Psoriatic Arthritis

New findings from two integrated Phase III studies showed treatment with Stelara (ustekinumab), from J&J Janssen Cilag, resulted in significantly greater inhibition of structural damage in patients with active Psoriatic Arthritis compared with placebo. Analyses from the PSUMMIT I and II trials showed treatment with either Stelara 45 mg or 90 mg resulted in significantly less change from baseline at week 24 in total Psoriatic Arthritis modified van der Heijde-Sharp (vdH-S) scores compared with placebo.

Stelara-treated patients from the combined data analysis of both trials demonstrated continued inhibition through one year and through two years according to findings from the PSUMMIT I trial. These results are presented at the 2013 Annual Meeting of the American College of Rheumatology. Stelara was approved for adult patients with Psoriatic Arthritis in both the US and EU during 2013.